The long-term goal of this proposal is to develop therapeutic strategies for the treatment of two human diseases, Oculo-Cerebro-Renal syndrome of Lowe (Lowe syndrome) and Dent disease, which result from loss-of-function mutations in the gene encoding the inositol 5-phosphatase OCRL. Lowe syndrome is a severe X-linked disorder characterized by reabsorption defects in the kidney proximal tubule (renal Fanconi syndrome), mental retardation and congenital cataracts. Dent disease is another X-linked disorder in which the clinical manifestations are limited to kidney defects that are similar to those observed in Lowe syndrome. While it is known that the main function of OCRL, an enzyme expressed by all cells of the body, is to dephosphorylate two bilayer phospholipids, PI(4,5)P2 and PI(3,4,5)P3 (members of the phosphoinositide family) at the 5 position of their inositol ring, the mechanisms through which a defect in the catalytic activity of this enzyme cause disease, and specifically kidney disease, remain unclear. The objective of this project is to elucidate such mechanisms. Strong evidence indicates that a main function of OCRL is to avoid accumulation of its substrates on membranes of the endocytic pathway. It is hypothesized that the resulting inappropriate intracellular accumulation of these lipids, primarily PI(4,5)P2, leads to ectopic actn nucleation and abnormal traffic and sorting of membrane proteins along the endocytic pathway. This effect is expected to have a dramatic impact on proximal tubule cells due the massive endocytic activity occurring at their actinrich apical pole. In this proposal we plan to elucidate he physiological function of the intracellular phosphoinositide pools controlled by OCRL, to determine how such pools regulate actin nucleation and endosomal traffic, and to establish how these events specifically affect the function of kidney proximal tubule cells in model mouse and cell lines.
This project will shed light on mechanisms of two severe kidney diseases and will thus represent a critical step towards their cure. The information acquired with this project will be relevant to the therapy of other conditions resulting from the impairment of kidney proximal tubule cells.
|Baskin, Jeremy M; Wu, Xudong; Christiano, Romain et al. (2016) The leukodystrophy protein FAM126A (hyccin) regulates PtdIns(4)P synthesis at the plasmaÂ membrane. Nat Cell Biol 18:132-8|
|Saheki, Yasunori; Bian, Xin; Schauder, Curtis M et al. (2016) Control of plasma membrane lipid homeostasis by the extended synaptotagmins. Nat Cell Biol 18:504-15|
|Dong, Rui; Saheki, Yasunori; Swarup, Sharan et al. (2016) Endosome-ER Contacts Control Actin Nucleation and Retromer Function through VAP-Dependent Regulation of PI4P. Cell 166:408-23|
|Reinisch, Karin M; De Camilli, Pietro (2016) SMP-domain proteins at membrane contact sites: Structure and function. Biochim Biophys Acta 1861:924-7|
|Chung, Jeeyun; Torta, Federico; Masai, Kaori et al. (2015) INTRACELLULAR TRANSPORT. PI4P/phosphatidylserine countertransport at ORP5- and ORP8-mediated ER-plasma membrane contacts. Science 349:428-32|
|Nakatsu, Fubito; Messa, Mirko; NÃ¡ndez, Ramiro et al. (2015) Sac2/INPP5F is an inositol 4-phosphatase that functions in the endocytic pathway. J Cell Biol 209:85-95|
|FernÃ¡ndez-Busnadiego, RubÃ©n; Saheki, Yasunori; De Camilli, Pietro (2015) Three-dimensional architecture of extended synaptotagmin-mediated endoplasmic reticulum-plasma membrane contact sites. Proc Natl Acad Sci U S A 112:E2004-13|
|Idevall-Hagren, Olof; LÃ¼, Alice; Xie, Beichen et al. (2015) Triggered Ca2+ influx is required for extended synaptotagmin 1-induced ER-plasma membrane tethering. EMBO J 34:2291-305|
|Chung, Jeeyun; Nakatsu, Fubito; Baskin, Jeremy M et al. (2015) Plasticity of PI4KIIIÎ± interactions at the plasma membrane. EMBO Rep 16:312-20|
|Idevall-Hagren, Olof; De Camilli, Pietro (2015) Detection and manipulation of phosphoinositides. Biochim Biophys Acta 1851:736-45|
Showing the most recent 10 out of 31 publications